◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › URGN

UroGen Pharma Ltd. (URGN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

UroGen Pharma Ltd. (URGN) operates in the Biotechnology industry and is headquartered in Princeton, United States with about 298 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, URGN reported $110M in revenue and ($154M) in net income.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Interactive charts & full statements → Open the URGN valuation workbench →

URGN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$110M$90M$83M$64M
Gross Profit$97M$82M$73M$57M
Operating Income (EBIT)($125M)($97M)($66M)($79M)
Net Income($154M)($127M)($102M)($110M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

URGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$51M$38M$28M$24M$20M
Gross Profit$47M$34M$24M$21M$18M
Operating Income (EBIT)($20M)($19M)($27M)($41M)($37M)
Net Income($24M)($26M)($33M)($50M)($44M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

URGN Free Cash Flow History

URGN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$200M$286M$178M$136M
Total Liabilities$306M$294M$244M$225M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive URGN viewer.

Other Companies in Biotechnology

← URBNAll stocksURI →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.